A recombinant fusion protein derived from the melanoma antigen MAGE-3 with potential immunostimulating and antineoplastic activities. Recognized by specific cytotoxic T lymphocytes, D1/3-MAGE-3-His fusion protein may boost antitumoral immune responses when used in a vaccine formulation. This recombinant chimeric protein is produced by fusing MAGE-3 with a lipidated protein D derived from H. influenzae at its N-terminus and a sequence of several histidine residues at its C-terminus.